Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENOPTIC vs AMIKIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Treatment of conjunctivitis,Treatment of blepharitis,Treatment of keratitis,Treatment of dacryocystitis,Prophylaxis of ocular infections following surgery or trauma
Treatment of serious gram-negative bacterial infections,Infections caused by susceptible strains of Pseudomonas aeruginosa, Escherichia coli, Proteus, Klebsiella, Serratia, and Enterobacter
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Not appreciably metabolized; excreted unchanged in urine.
Amikacin is not metabolized; it is excreted unchanged primarily by glomerular filtration.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
20-30% bound to serum albumin.
0-10% (low binding to albumin).
0.2-0.3 L/kg; low Vd indicates limited tissue distribution (mainly extracellular fluid).
0.25 L/kg in adults; higher in neonates and edema states (0.3-0.4 L/kg), indicating distribution into extracellular fluid.
Oral: 60-80% (first-pass effect); ophthalmic: negligible systemic absorption (≤1%).
IM: 100% (complete absorption); oral: <1% (not absorbed).
No dose adjustment required for ophthalmic use due to minimal systemic absorption.
GFR 30-59 m L/min: extend dosing interval to every 12-24 hours; GFR 15-29 m L/min: extend to every 24-48 hours; GFR <15 m L/min: extend to every 48-72 hours or consider peritonitis dosing; adjust based on serum levels
No dose adjustment required for ophthalmic use due to minimal systemic absorption.
No specific Child-Pugh based adjustments required; amikacin is minimally hepatically metabolized; monitor renal function as primary clearance route
Same as adult dosing: 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially.
Neonates: 15-20 mg/kg/day IV/IM every 12-24 hours depending on gestational age; Infants and children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day
Same as adult dosing; no specific adjustment needed for ophthalmic use.
Start with lower initial doses based on renal function; monitor renal function and serum amikacin levels closely; usual initial dose reduction to 7.5 mg/kg every 12-24 hours based on estimated GFR
Not applicable (no FDA black box warnings for Genoptic).
Amikacin can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity (both vestibular and auditory) can occur in patients with pre-existing renal damage and in those with normal renal function treated with higher doses or for longer periods than recommended.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Discontinue use if sensitization or irritation occurs.,Monitor for signs of systemic absorption, especially in patients with renal impairment.,Avoid prolonged use due to risk of secondary infections.
Neurotoxicity (ototoxicity) and nephrotoxicity; neuromuscular blockade; respiratory paralysis; cross-allergenicity among aminoglycosides; monitoring of renal function and drug levels recommended.
Hypersensitivity to gentamicin or any component of the formulation.,History of toxic reactions to aminoglycosides.
Hypersensitivity to amikacin or any aminoglycoside; history of ototoxicity with prior aminoglycoside use.
None reported with ophthalmic use. No dietary restrictions.
No significant food interactions. Maintain adequate hydration. Avoid alcohol as it may worsen side effects.
Category C: No adequate studies in pregnant women. In animal studies, gentamicin (the active ingredient in GENOPTIC) has been associated with fetal renal toxicity and ototoxicity when administered systemically at high doses. Topical ophthalmic use results in minimal systemic absorption, but risk cannot be excluded. Avoid use during first trimester unless clearly needed.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicity, ototoxicity) at doses similar to or lower than human doses. Amikacin crosses the placenta. First trimester: Risk cannot be excluded; use only if clearly needed. Second and third trimesters: Potential for fetal nephrotoxicity and ototoxicity; avoid use unless necessary for serious infections. Risk category D (positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience).
Unknown if gentamicin is excreted in human milk after topical ophthalmic administration; systemic absorption is low. Caution advised, consider developmental and health benefits of breastfeeding along with mother's clinical need for GENOPTIC. No M/P ratio available.
Amikacin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. After intramuscular administration of 500 mg, peak milk concentrations are about 1-2 mcg/m L. Because of low oral bioavailability (poorly absorbed from the GI tract), systemic effects in the nursing infant are unlikely. However, theoretical risk of alteration of infant gut flora and direct exposure. Use with caution, especially in premature infants or those with renal impairment. The American Academy of Pediatrics considers amikacin compatible with breastfeeding.
No dose adjustment required for topical ophthalmic gentamicin during pregnancy; systemic absorption is negligible and pharmacokinetics unchanged. Use standard dosing as prescribed.
Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, increased renal clearance) may require dose adjustments, but specific guidelines are not established. Generally, standard dosing based on actual body weight and renal function is used. Therapeutic drug monitoring is recommended, especially in third trimester or with concurrent renal impairment. Dose adjustments should be based on serum levels to maintain therapeutic efficacy while minimizing toxicity. No dose reduction is universally recommended; individualize based on renal function and clinical response.
GENOPTIC (gentamicin sulfate ophthalmic solution) is an aminoglycoside antibiotic for ocular infections. Ensure proper diagnosis via culture and sensitivity. Use with caution in patients with renal impairment or myasthenia gravis due to potential systemic absorption. Monitor for hypersensitivity reactions; discontinue if keratitis or corneal ulceration occurs. Avoid prolonged use to prevent superinfection with resistant organisms, including fungi. Not for intraocular injection.
Monitor peak (20-30 mcg/m L) and trough (1-8 mcg/m L) serum levels; adjust dose based on renal function. Avoid concurrent use with other ototoxic/nephrotoxic drugs. Use extended-interval dosing (e.g., 15-20 mg/kg IV once daily) when possible. Assess for vestibular toxicity (ataxia, vertigo) and cochlear toxicity (tinnitus, high-frequency hearing loss).
Wash hands before and after use.,Tilt head back, pull down lower eyelid, and apply 1-2 drops into the conjunctival sac.,Avoid touching the dropper tip to any surface, including the eye, to prevent contamination.,Do not wear contact lenses during treatment unless directed by your doctor.,Complete the full course of therapy even if symptoms improve.,Report any signs of allergic reaction, such as rash, itching, or swelling of the eyes/face.,May cause temporary blurred vision; avoid driving or operating machinery until vision clears.
Report any hearing loss, ringing in ears, dizziness, or unsteadiness immediately.,Drink plenty of fluids to help prevent kidney damage.,Avoid taking other aminoglycosides or strong diuretics unless prescribed.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENOPTIC vs AMIKIN, answered by our medical review team.
GENOPTIC is a Aminoglycoside Antibiotic that works by Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and production of nonfunctional proteins.. AMIKIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENOPTIC and AMIKIN depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENOPTIC is: Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.. The standard adult dose of AMIKIN is: 15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENOPTIC and AMIKIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENOPTIC is classified as Category C. Category C: No adequate studies in pregnant women. In animal studies, gentamicin (the active ingredient in GENOPTIC) has been associated with fetal renal toxicity and ototoxicity w. AMIKIN is classified as Category C. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicit. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.